Researchers at the RIKEN Center for Developmental Biology (CDB) have successfully transplanted retinal pigment cells derived from stem cells of one monkey into the eyes of other monkeys without rejection and without the need for immunosuppressant drugs. Published in Stem Cell Reports, the study shows that this procedure is possible as long as a set of cells called the MHC are genetically matched between the host monkey and the new retinal cells.
A realistic hope of modern medicine is to replace damaged tissue with healthy cells grown in the lab. Currently, adult cells can be reprogrammed into stem cells, and then re-differentiated and grown into desired cell types. The researchers at RIKEN CDB led by Masayo Takahashi have already begun a clinical transplant trial in people with age-related macular degeneration. The team grew retinal pigment cells from induced pluripotent stem cells (iPSCs) and transplanted them into the damaged retina of a human participant. In order to avoid tissue rejection, they used autologous iPSCs—iPSCs that were created from the recipient’s own skin cells.
While this method is sound, producing autologous iPSCs is costly. Additionally, because the cells must grow at the same rate as they do during normal development, a person would have to wait more than a year before a transplant could be performed.
Notes lead author Sunao Sugita, “In order to make iPSC transplantation a practical reality, the current goal is to create banks of iPSC-derived tissues that can be transplanted into anyone as they are needed. However, immune responses and tissue rejection are big issues to overcome when transplanting tissue derived from other individuals.”
The new study tested a technique called MHC matching as a way to overcome this issue. Major histocompatibility complexes (MHCs) are a sets of cell-surface proteins found in all cells that function in the immune system. In humans, MHCs are also called human leukocyte antigens (HLAs). There are many genetic variations of MHCs, and after transplantation, if the MHCs of the transplanted cells are not recognized by the T cells of the host immune system, there is an immune response and the tissue is rejected.
To test whether MHC matching is a viable method, the team used retinal pigment cells that were grown from monkey iPSCs in the iPS cell bank at the Center for iPS Cell Research and Application, Kyoto University. They transplanted the cells into the subretinal space in monkeys with either genetically matched or non-matched MHCs.
The researchers found that these transplanted cells survived without rejection for at least 6 months in MHC-matched monkeys, without using any of the usually necessary immunosuppressant drugs. In contrast, rejection was relatively quick in the MHC-mismatched monkeys. Immunohistochemical examination showed that infiltration by inflammatory cells was only present in the transplanted grafts of MHC-mismatched monkeys. In vitro, the team saw that T cells failed to respond to the iPSC-derived retinal pigment cells if they were from an MHC-matched monkey.
In a separate study published in the same issue of Stem Cell Reports, the researchers saw similar results when they repeated this last experiment with human T cells and HLA-matched or unmatched retinal pigment cells grown from IPSCs.
Now that we have established the lack of immune response in monkeys and in human cells in vitro,” explains Sugita, “using the iPS cell bank appears to be a viable solution, at least in the case of retinal pigment epithelial cell transplantation.”
“In the next clinical trial,” continues Sugita, “we plan to use allogeneic iPS-retinal pigment epithelial cells from HLA homozygote donors. The clinical data after the transplantation will allow us to see if the iPS cell bank is truly useful or not. If so, I think this type of transplantation can become standard treatment within 5 years.”
The Latest on: iPSC transplantation
via Google News
The Latest on: iPSC transplantation
- Global Stem Cell Market Value is Expected to Reach $28.49 Billion by 2022 - A Report by TBRCon August 13, 2019 at 9:30 am
IPSC are obtained from blood or skin cells ... intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain ...
- Understanding Metabolism and Maturation of iPSC Cardiomyocyteson July 4, 2019 at 12:59 pm
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have been shown to be a great tool for modeling CVD and drug screening, and are also being used for transplantation into injured ...
- Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signatureon April 10, 2019 at 8:38 am
Dr. Meisel) and the Institute for Transplantation Diagnostics and Cell Therapeutics ... (2019, April 10). Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signature. ScienceDaily.
- UC San Diego Health treats first cancer patient with iPSC-derived cell therapyon April 2, 2019 at 12:29 am
The off-the-shelf, iPSC-derived natural killer (NK ... His original goal was to make early human iPSCs for use in blood and marrow transplant as a supplement or substitute for donor cells. As the ...
- Induced Pluripotent Stem Cells (iPSC): Meaning, Function and Significanceon February 21, 2019 at 9:18 am
Whereas additional researches are going on and no doubt iPSC is a useful tool for drug development and modelling of diseases. Also, scientists use them in transplantation medicine. Do you know about ...
- Genetic matching technique means no rejection for transplanted cellson September 18, 2018 at 5:00 pm
In research that could significantly improve the viability of human retinal cell transplant methods and help restore ... RIKEN Center for Developmental Biology (CDB) has used a genetic matching ...
- Single transplantation of therapeutic macrophages improves rare lung disease in miceon August 9, 2018 at 8:02 am
On August 9 in the journal Stem Cell Reports, researchers in Germany demonstrate that a single transplantation of murine macrophages derived from induced pluripotent stem cells (iPSC) into the lungs ...
- Induced Pluripotent Stem Cell (iPS Cell): 2018-2022 Industry Analysis & Forecaston August 2, 2018 at 1:41 am
2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPS cells into humans ... Dr. Takahashi was investigating the safety of iPSC-derived cell sheets ...
- American Journal of Respiratory and Critical Care Medicineon July 31, 2018 at 5:00 pm
Rationale: Although the transplantation of induced pluripotent stem cell (iPSC)–derived cells harbors enormous potential for the treatment of pulmonary diseases, in vivo data demonstrating clear ...
via Bing News